ezrin在乳腺癌中的表达及其临床意义

目的 探讨乳腺癌组织中ezrin蛋白的表达及其临床意义.方法 应用免疫组化S-P方法,检测63例乳腺癌组织中ezrin的表达情况.结果 ezrin总的表达率为55.56%(35/63),ezrin表达率随着淋巴结转移增多和临床分期的增高而升高(χ2分别为7.718、6.760,P分别为0.005、0.009).无病生存时间在5年以上患者的ezrin表达率[33.33%(10/30)]显著低于无病生存时间不足5年(远处转移)或5年内死亡的患者(75.76%,25/33,χ2=11.455,P=0.001),但是ezrin的表达和肿瘤大小、月经及年龄无相关性(χ2分别为0.060、0.423、0.319,P均>0.05).结论 检测ezrin在乳腺癌中的表达可能有助于对其预后的判断.

Expression and clinical significance of ezrin in breast carcinomas

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.